UNIVERSITY OF OKLAHOMA - TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201 BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS
Key Details
Description
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201 BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS
Context & Analysis
On Feb 26, 2026, Department of Health and Human Services obligated $982,258 to UNIVERSITY OF OKLAHOMA for task order title: preventing lung adenocarcinoma (luad) using trail inducing agent, onc201 base contract title: prevent preclinical drug development program: preclinical efficacy and intermediate bio…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in OKLAHOMA CITY, OK. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.